A therapy can clear every regulatory hurdle and still face difficult questions at the formulary or reimbursement stage. That gap between regulatory approval and patient access is where health economics and outcomes research (HEOR) increasingly matters. Clinical trial results remain fundamental, but healthcare decision-makers need... Continue reading
Return to previous page
Category: Blogs
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet despite this sophistication, many commercial and market access decisions still feel uncertain not because teams lack data, but because... Continue reading
Every major oncology congress has its headline moments: a trial that changes practice, a therapy that exceeds expectations, or a new mechanism that suddenly becomes the industry’s next big focus. But ESMO is rarely just about individual trial results. It is where the oncology community... Continue reading
The first wave of obesity innovation proved a simple point: meaningful weight loss can be delivered at scale if patients can start therapy, stay on it, and afford it. GLP-1s turned obesity into one of the most commercially successful therapeutic categories in pharma history. By... Continue reading
A therapy can post best-in-class trial data and still stall at launch. Not because the science was wrong, but because nobody could tell a payer what happens after the trial ends, when the drug meets real patients, real budgets, and real infrastructure. That gap is... Continue reading
A drug’s clinical trial data tells you how it performs under ideal conditions. It doesn’t tell you where your patients actually are, why they’re taking three years to get diagnosed, which physicians are missing them entirely, or where they’ll fall out of the funnel between... Continue reading
Why the most successful commercial launches are built long before reimbursement discussions begin For years, market access has been treated as a milestone. From developing the therapy, to completing the clinical trials and securing regulatory approval. Then prepare for pricing, reimbursement, and payer negotiations. While... Continue reading
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient’s life, together, created a widely accepted logic: high prices were simply the cost of innovation. That... Continue reading
Real-world evidence is no longer optional in market access discussions. Payers expect it. HTA bodies ask for it. Internal teams invest heavily in generating it. And yet, a quiet reality persists: most RWE never meaningfully influences payer decisions. It isn’t rejected outright. It’s acknowledged, parked,... Continue reading
For many biopharma teams, Phase III is treated as the final mountain to climb. Once efficacy and safety are proven, commercial readiness is assumed to follow naturally. In reality, that assumption is one of the most costly missteps in drug development. More assets than ever... Continue reading
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
